Pharmacokinetic Study of STN1012600 Ophthalmic Solution in Healthy Adult Males Volunteers

Santen

Status and phase: Completed; Phase 1

Conditions: Healthy Adult Males Volunteers

Treatments: Drug: STN1012600 ophthalmic solution 0.002%

Study type: Interventional

Funder types: Industry

Identifiers

NCT05905653

101260007LT

Details and patient eligibility

About

To evaluate the safety and plasma pharmacokinetics of STN1012600 ophthalmic solution 0.002% (1 drop once daily for 7 days) in healthy adult male subjects.

Enrollment: 8 patients

Sex: Male

Ages: 18 to 35 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Subjects who can comply with scheduled visits and the examination and observation as specified in the clinical study protocol

Exclusion criteria

• Subjects have a disease and/or abnormal laboratory value which is considered inappropriate from safety evaluation perspective
• Subjects who are inappropriate as participants in this study in the opinion of the investigator or sub investigator

Trial design

Primary purpose: Treatment

Allocation: N/A

Interventional model: Single Group Assignment

Masking: None (Open label)

---

8 participants in 1 patient group

STN1012600 0.002%

Experimental group

Treatment:

Drug: STN1012600 ophthalmic solution 0.002%